Comparison of Two Standard Treatment Approaches in Locoregionally Advanced Nasopharyngeal Carcinoma.

IF 0.6 Q4 ONCOLOGY South Asian Journal of Cancer Pub Date : 2022-07-01 DOI:10.1055/s-0042-1742724
Issa Mohamad, Fawzi Abu-Hijleh, Ebrahim Mayta, Taher Abu-Hejleh, Wisam Al-Gargaz, Abdellatif Al Mousa, Ramiz Abu-Hijlih, Ali Hosni
{"title":"Comparison of Two Standard Treatment Approaches in Locoregionally Advanced Nasopharyngeal Carcinoma.","authors":"Issa Mohamad,&nbsp;Fawzi Abu-Hijleh,&nbsp;Ebrahim Mayta,&nbsp;Taher Abu-Hejleh,&nbsp;Wisam Al-Gargaz,&nbsp;Abdellatif Al Mousa,&nbsp;Ramiz Abu-Hijlih,&nbsp;Ali Hosni","doi":"10.1055/s-0042-1742724","DOIUrl":null,"url":null,"abstract":"<p><p>Issa Mohamad<b>Objectives</b>  To compare outcomes and toxicity of two standard treatment approaches of advanced nasopharyngeal carcinoma (NPC). <b>Methods</b>  Between 2010 and 2016, patients with NPC, stage II-IVa, treated with induction chemotherapy (IC) (TPF), followed by concurrent chemoradiotherapy (CCRT) (induction group), or CCRT, followed by adjuvant chemotherapy (AC) (PF) (no-induction group), were retrospectively reviewed. CCRT included platinum-based chemotherapy with intensity-modulated radiotherapy. Survival outcomes, the pattern of failures, toxicity, and predictors for survival outcomes were evaluated. <b>Results</b>  A total of 110 patients were included, 65 in the induction group and 45 in the no-induction group. There were no significant differences in the DFS and overall survival (OS) at 3 years between the two groups. On multivariate analysis, performance status (1 vs. 0) predicted worse OS. The 3-year cumulative incidence rates for local, regional, and distant failures were 58.5% (95% confidence interval [CI]: 8.4-89%), 58.00% (95% CI: 8-88.8%), and 63.90% (95% CI: 14.1-90.2%), respectively. IC had more frequent acute grade (G) II anemia (13 vs. 1, <i>p</i>  < 0.01), late G II brain toxicity (4 vs. 1, <i>p</i>  < 0.01), and late G II dysphagia (32 vs. 11, <i>p</i>  = 0.01). <b>Conclusions</b>  Survival outcomes were comparable between the two groups. IC had more frequent acute G II anemia and late G II brain and esophageal toxicities.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"11 3","pages":"223-228"},"PeriodicalIF":0.6000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/3a/10-1055-s-0042-1742724.PMC9803531.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"South Asian Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0042-1742724","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Issa MohamadObjectives  To compare outcomes and toxicity of two standard treatment approaches of advanced nasopharyngeal carcinoma (NPC). Methods  Between 2010 and 2016, patients with NPC, stage II-IVa, treated with induction chemotherapy (IC) (TPF), followed by concurrent chemoradiotherapy (CCRT) (induction group), or CCRT, followed by adjuvant chemotherapy (AC) (PF) (no-induction group), were retrospectively reviewed. CCRT included platinum-based chemotherapy with intensity-modulated radiotherapy. Survival outcomes, the pattern of failures, toxicity, and predictors for survival outcomes were evaluated. Results  A total of 110 patients were included, 65 in the induction group and 45 in the no-induction group. There were no significant differences in the DFS and overall survival (OS) at 3 years between the two groups. On multivariate analysis, performance status (1 vs. 0) predicted worse OS. The 3-year cumulative incidence rates for local, regional, and distant failures were 58.5% (95% confidence interval [CI]: 8.4-89%), 58.00% (95% CI: 8-88.8%), and 63.90% (95% CI: 14.1-90.2%), respectively. IC had more frequent acute grade (G) II anemia (13 vs. 1, p  < 0.01), late G II brain toxicity (4 vs. 1, p  < 0.01), and late G II dysphagia (32 vs. 11, p  = 0.01). Conclusions  Survival outcomes were comparable between the two groups. IC had more frequent acute G II anemia and late G II brain and esophageal toxicities.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
局部进展期鼻咽癌两种标准治疗方法的比较。
目的比较两种标准治疗晚期鼻咽癌(NPC)的疗效和毒性。方法回顾性分析2010 - 2016年期间,接受诱导化疗(IC) +同步放化疗(CCRT)(诱导组)或CCRT +辅助化疗(AC) (PF)(非诱导组)治疗的II-IVa期鼻咽癌患者。CCRT包括铂基化疗加调强放疗。对生存结果、失败模式、毒性和生存结果的预测因素进行评估。结果共纳入110例患者,其中诱导组65例,非诱导组45例。两组患者的DFS和3年总生存期(OS)无显著差异。在多变量分析中,性能状态(1 vs. 0)预示着更差的OS。局部、区域和远处失败的3年累积发病率分别为58.5%(95%可信区间[CI]: 8.4-89%)、58.00% (95% CI: 8-88.8%)和63.90% (95% CI: 14.1-90.2%)。IC患者急性(G) II级贫血发生率更高(13 vs. 1, p p p = 0.01)。结论两组患者的生存结局具有可比性。IC有更频繁的急性G期贫血和晚期G期脑和食管毒性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
80
审稿时长
35 weeks
期刊最新文献
Staging and Management of Cervical Cancer at the Colposcopy Clinic of Bangabandhu Sheikh Sheikh Mujib Medical University (BSMMU), Bangladesh. COVID-19 Impact on Newly Diagnosed Breast Cancers at Regional Cancer Centre, Thiruvananthapuram-An Audit. Do Uro-Oncology Day Care Procedures Need to Be Differed during COVID-19 Pandemic?-An Experience from Tertiary Cancer Care Center. Colorectal Origin: A Marker of Favorable Outcome in Krukenberg Tumor? Results from Clinical and Prognostic Analysis. Cytogenetic Alterations and Correlation with Age and Gender in Patients of Multiple Myeloma: A Study from a Tertiary Care Center in Eastern India.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1